menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Specialty Provider Insights on Evolving Paradigms in COPD: Live Broadcast

This live broadcast will review dual-bronchodilation therapy, advances in triple therapy, new treatment recommendations & inhaler strategies in COPD.
1.00 available credits
This live broadcast will review dual-bronchodilation therapy, advances in triple therapy, new treatment recommendations & inhaler strategies in COPD.
1.00 available credits
Enroll in this meeting
October 20, 2019
07:00 PM - 08:00 PM CDT
Online
Enrollment Fee: Free
Free
  • Overview

    Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous disease. Management of  patients with COPD has been complicated by evolving clinical guidelines that incorporate novel escalation strategies with dual long-acting ß agonist (LABA)/long-acting muscarinic antagonist (LAMA) bronchodilation treatments, and LAMA/LABA/inhaled corticosteroid (ICS) triple therapy. Dual bronchodilation and triple therapy treatment options are both now available as fixed-dose combination inhalers. Despite updated recommendations, there is limited practical guidance on individualizing therapy or identifying patients who may benefit from treatment escalation. In addition, lack of knowledge of appropriate COPD inhaler use and self-management strategies persist among patients and caregivers, precluding optimal therapeutic benefit and clinical outcomes. This live broadcast educational activity will feature 3 international experts in COPD who will review and discuss the clinical science behind dual-bronchodilation therapy, advances in triple therapy, and the new COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.

    GOAL

    This goal of this activity is for physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD in pulmonology settings to develop the knowledge base to incorporate dual- and triple-bronchodilation management strategies into their practice, based on guideline recommendations, and to improve individualized treatment plans for their patients with COPD.

  • Faculty

  • Target Audience

    This educational initiative is designed for pulmonology, critical care/intensive care, and other specialty physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD.

  • Learning Objectives

    • Explain key clinical findings and related initial and escalation therapy clinical guidelines, regarding dual bronchodilation and ICS-containing inhalation maintenance therapy for COPD.
    • Propose strategies to recognize exacerbations in COPD and optimize escalation therapy to address disease burden.
    • Identify tactics to provide COPD-specific patient education and inhaler training.
    • Develop appropriate inhaled maintenance treatment strategies based on patient symptoms, exacerbation risks, inhaler device, and clinical guidelines.
  • Agenda

    AGENDA
    Welcome and Introductions 

    Meeting the Burden of COPD in the Specialty Setting
    James F. Donohue, MD

    Keeping up with the Latest Therapeutic Advances: A Focus on Combination Therapies
    Nicola Alexander Hanania, MD, MS, FCCP, FERS

    Current COPD Recommendations and Implementation of Individualized Treatment and Inhaler Strategies for COPD
    MeiLan K. Han, MD

    Questions and Answer Session
    Faculty Panel

  • Continuing Education Information

    JOINT ACCREDITATION STATEMENT – In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education – The Postgraduate Institute for Medicine  designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

    Name of Faculty or Presenter 
    James F. Donohue, MD                                          
    Reports receiving consulting fees from AstraZeneca, GlaxoSmithKline, Mylan, Sunovion Pharmaceuticals Inc, and Theravance Biopharma; and receiving fees for non-CME/CE services from GlaxoSmithKline, Mylan, and Theravance Biopharma.

    MeiLan K. Han, MD                                                 
    Reports receiving royalties from UpToDate.com; receiving consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Mylan; and receiving research support from Novartis and Sunovion.

    Nicola A. Hanania, MD, MS                                   
    Reports receiving consulting fees from AstraZeneca, Genentech Inc, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals Inc, and Sanofi Genzyme; and reports performing contracted research for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gossamer Bio, Novartis, and Sanofi Genzyme.

    Planners and Managers – The PIM planners and managers have nothing to disclose.
    The following ASiM CE, LLC planners and managers, Jessica Marshall, PhD, and Jessica Epps, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

     

    FEE INFORMATION – There is no fee for this educational activity.

  • Commercial Support

    This educational activity is supported by an independent educational grant from GlaxoSmithKline.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Postgraduate Institute for Medicine and ASiM.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/16/19